Media Room Menu
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Feb 6, 2020JDRF T1D Fund Study Estimates 2.3 Million People at Risk Globally to Develop Stage 3 T1D, Which Already Affects 18 Million People Globally
-
Jan 30, 2020- Acid sphingomyelinase deficiency (ASMD) is a rare, progressive and potentially life-threatening disease for which no treatments are approved
-
Jan 28, 2020If approved, Dupixent would be the first biologic medicine available in the U.S. for these children
-
Jan 23, 2020* Synthorx, Inc. is now a fully owned subsidiary of Sanofi
-
Dec 12, 2019Expects to Complete Submission of a BLA for PRV-031 (Teplizumab) in Q4 2020
-
Dec 9, 2019- U.S.-based, state of the art facilities to be established for sustainable production of adjuvanted recombinant vaccine for use in the event of a pandemic
-
Nov 21, 2019- Sutimlimab, an investigational targeted C1s inhibitor, met its primary efficacy endpoint in Phase 3 trial for patients with cold agglutinin disease (CAD)
-
Nov 6, 2019*Oncology: New data from investigational isatuximab pivotal study for the treatment of relapsed/refractory multiple myeloma
-
Nov 5, 2019- PRV-031 (teplizumab) Granted Breakthrough Therapy and PRIME Designations -
-
Nov 4, 2019* Will be available in fall 2020, in time for the 2020-2021 flu season
-
Oct 22, 2019-Study Did Not Achieve Primary Endpoint Due to High Placebo Effect-
-
Oct 15, 2019- One of the first digital manufacturing facilities in the world to use continuous, intensified biologics production technology
-
Oct 9, 2019Add-on payment to provide additional Medicare reimbursement for Medicare patients prescribed Cablivi in eligible hospital inpatient settings
-
Sep 30, 2019- CARD is a treatment sequencing trial investigating the efficacy and safety of Jevtana versus abiraterone or enzalutamide after disease progression following initial androgen receptor-targeted agent therapy and docetaxel
-
Sep 26, 2019- T1D Fund Executive Chairman and Former Bain Capital Managing Director Brings Extensive Financial Expertise and Deep Knowledge of Therapeutics Landscape -
-
Sep 24, 2019- FDA Meeting Expected in Q4 2019 and BLA Submission for PRV-031 (teplizumab) Targeted for Q4 2020 -
-
Sep 18, 2019Understand AD program brings together a team of experts to help a teen with severe atopic dermatitis (AD) and his parents navigate the disease
-
Sep 16, 2019- Collaboration aims to provide a connected device experience for millions of people living with diabetes using insulin
-
Aug 28, 2019Court rules in favor of Sanofi and Regeneron in ongoing Praluent® (alirocumab) patent litigation
-
Aug 20, 2019- Appoints Dr. Sherron Kell as SVP of Clinical Development and Program Lead for PRV-031 (Teplizumab) -
-
Aug 8, 2019-Bispecific Diabody Designed to Intercept B-Cell Mediated Autoimmune Diseases-
-
Aug 6, 2019U.S. FDA submission for children planned for 4Q 2019
-
Aug 6, 2019PRV-031 Granted Breakthrough Therapy Designation for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals
-
Jun 26, 2019* First biologic medicine for adults with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP)
-
Jun 9, 2019Results from the NIH-Sponsored "At-Risk" Study Published in The New England Journal of Medicine and Presented at the American Diabetes Association Annual Meeting
-
Jun 2, 2019News Summary: * Isatuximab, an investigational anti-CD38 monoclonal antibody, added to pomalidomide and dexamethasone prolonged progression free survival by 5 months compared to pomalidomide and dexamethasone alone (11.53 vs. 6.47 months, p=0.001, HR 0.596) * Overall response rate significantly greater with isatuximab combination therapy compared to pomalidomide and dexamethasone (60% vs. 35%, p<0.0001) * First positive randomized Phase 3 trial to evaluate an antibody in combination with pomalidomide and dexamethasone presented at this year’s ASCO annual meeting * European Medicines Agency accepted for review the Marketing Authorization Application for isatuximab
-
May 15, 2019- Pivotal Phase 3 data evaluated isatuximab (anti-CD38) in combination with pomalidomide/dexamethasone in prolonging progression-free survival in relapsed/refractory multiple myeloma
-
May 15, 2019* New data at ASCO include more than double the patients previously reported; median overall survival still not reached with a median follow-up of up to 17 months
-
May 8, 2019PROTECT Pivotal Phase 3 Clinical Study Initiated in Patients with Recent Onset Type 1 Diabetes
-
May 7, 2019* Only biologic approved in the EU for severe asthma with type 2 inflammation, as characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO)